$0.9700
At close: Apr 14, 8:09 AM EDT
$1.03
0.066.19%
After Hours: 8:09 AM EDT
Comments
Loading...
Unity Biotechnology Analyst Ratings and Price Targets | NASDAQ:UBX | Benzinga
Unity Biotechnology Inc has a consensus price target of $6.57 based on the ratings of 8 analysts. The high is $10 issued by Roth MKM on May 31, 2023. The low is $4 issued by Chardan Capital on March 25, 2025. The 3 most-recent analyst ratings were released by Chardan Capital, HC Wainwright & Co., and HC Wainwright & Co. on March 25, 2025, March 25, 2025, and March 24, 2025, respectively. With an average price target of $4 between Chardan Capital, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 288.35% upside for Unity Biotechnology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
HC Wainwright & Co.
Rodman & Renshaw
HC Wainwright & Co.
Roth MKM
1calculated from analyst ratings
Analyst Ratings for Unity Biotechnology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/25/2025 | Buy Now | 288.35% | Chardan Capital | Daniil Gataulin35% | $6 → $4 | Maintains | Buy | Get Alert |
| 03/25/2025 | Buy Now | 288.35% | HC Wainwright & Co. | Matthew Caufield32% | $8 → $4 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 288.35% | HC Wainwright & Co. | Matthew Caufield32% | $8 → $4 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | 482.52% | Chardan Capital | Daniil Gataulin35% | $6 → $6 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | 676.7% | HC Wainwright & Co. | Matthew Caufield32% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | 482.52% | Chardan Capital | Daniil Gataulin35% | → $6 | Initiates | → Buy | Get Alert |
| 08/22/2024 | Buy Now | 676.7% | Rodman & Renshaw | — | → $8 | Initiates | → Buy | Get Alert |
| 08/08/2024 | Buy Now | 676.7% | HC Wainwright & Co. | Andrew Fein52% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 676.7% | HC Wainwright & Co. | Andrew Fein52% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | 676.7% | HC Wainwright & Co. | Andrew Fein52% | $10 → $8 | Maintains | Buy | Get Alert |
| 11/16/2023 | Buy Now | — | Wedbush | Andreas Argyrides69% | — | Upgrade | Neutral → Outperform | Get Alert |
| 11/14/2023 | Buy Now | 870.87% | HC Wainwright & Co. | Matthew Caufield32% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 870.87% | HC Wainwright & Co. | Matthew Caufield32% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 94.17% | Wedbush | Andreas Argyrides69% | $3 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 05/31/2023 | Buy Now | 870.87% | Roth MKM | Dylan Dupuis61% | → $10 | Initiates | → Buy | Get Alert |
| 05/26/2023 | Buy Now | 482.52% | Citigroup | Yigal Nochomovitz54% | $5 → $6 | Maintains | Buy | Get Alert |
| 05/10/2023 | Buy Now | 870.87% | HC Wainwright & Co. | Matthew Caufield32% | → $10 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | 191.26% | Wedbush | Andreas Argyrides69% | $5 → $3 | Maintains | Outperform | Get Alert |
| 03/28/2023 | Buy Now | 482.52% | Mizuho | Salim Syed42% | $12 → $6 | Maintains | Buy | Get Alert |
| 03/28/2023 | Buy Now | 385.44% | Wedbush | Andreas Argyrides69% | $35 → $5 | Maintains | Outperform | Get Alert |
| 03/28/2023 | Buy Now | 870.87% | HC Wainwright & Co. | Matthew Caufield32% | → $10 | Reiterates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | 385.44% | Citigroup | Yigal Nochomovitz54% | $15 → $5 | Maintains | Buy | Get Alert |
| 03/16/2023 | Buy Now | 3298.06% | Wedbush | Andreas Argyrides69% | → $35 | Reiterates | → Outperform | Get Alert |
| 03/16/2023 | Buy Now | 870.87% | HC Wainwright & Co. | Andrew Fein52% | → $10 | Reiterates | → Buy | Get Alert |
| 02/15/2023 | Buy Now | 870.87% | HC Wainwright & Co. | Andrew Fein52% | → $10 | Maintains | Buy | Get Alert |
| 11/16/2022 | Buy Now | 1065.05% | Mizuho | Salim Syed42% | $80 → $12 | Maintains | Buy | Get Alert |
| 11/09/2022 | Buy Now | 870.87% | HC Wainwright & Co. | Andrew Fein52% | $12 → $10 | Maintains | Buy | Get Alert |
| 11/02/2022 | Buy Now | 3395.15% | Wedbush | Andreas Argyrides69% | $4 → $36 | Maintains | Outperform | Get Alert |
| 08/16/2022 | Buy Now | 676.7% | Mizuho | Salim Syed42% | $70 → $80 | Maintains | Buy | Get Alert |
| 08/15/2022 | Buy Now | 676.7% | Citigroup | Yigal Nochomovitz54% | $50 → $80 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 385.44% | Citigroup | Yigal Nochomovitz54% | $60 → $50 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Unity Biotechnology (UBX) stock?
The latest price target for Unity Biotechnology (NASDAQ:UBX) was reported by Chardan Capital on March 25, 2025. The analyst firm set a price target for $4.00 expecting UBX to rise to within 12 months (a possible 288.35% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Unity Biotechnology (UBX)?
The latest analyst rating for Unity Biotechnology (NASDAQ:UBX) was provided by Chardan Capital, and Unity Biotechnology maintained their buy rating.
When was the last upgrade for Unity Biotechnology (UBX)?
The last upgrade for Unity Biotechnology Inc happened on November 16, 2023 when Wedbush raised their price target to N/A. Wedbush previously had a neutral for Unity Biotechnology Inc.
When was the last downgrade for Unity Biotechnology (UBX)?
The last downgrade for Unity Biotechnology Inc happened on June 26, 2023 when Wedbush changed their price target from $3 to $2 for Unity Biotechnology Inc.
When is the next analyst rating going to be posted or updated for Unity Biotechnology (UBX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unity Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unity Biotechnology was filed on March 25, 2025 so you should expect the next rating to be made available sometime around March 25, 2026.
Is the Analyst Rating Unity Biotechnology (UBX) correct?
While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a maintained with a price target of $6.00 to $4.00. The current price Unity Biotechnology (UBX) is trading at is $1.03, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.